QURE logo uniQure : QURE

QURE

Stock Data

$0.00

Change up

$0.00 (0.00%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

uniQure N.V., based in Amsterdam, specializes in pioneering gene therapies for rare and severe diseases. Its notable product, HEMGENIX, targets hemophilia B and has successfully completed a crucial Phase III trial. The company is also advancing treatments for Huntington’s disease, ALS, temporal lobe epilepsy, Fabry disease, Alzheimer’s, and Parkinson’s through various stages of clinical and preclinical development. Founded in 1998, uniQure is at the forefront of genetic medicine, aiming to transform the lives of patients with groundbreaking treatments.

Latest Activity

QUREuniQure N.V.
Q2 2026
EPS
-$1.22
est -$0.71-72.4%
Revenue
$6M
est $5M+24.0%

uniQure's gene therapy pipeline pivots into focus as the company plans a Huntington's disease BLA submission in Q3, four-year clinical data due in September, and a 2030 cash runway into place despite an EPS miss tied to foreign currency swings and warrant fair value losses.

Quarterly EPS — reported vs estimate

All uniQure Articles

12 Articles